This study is designed for adults who receive a kidney transplant. It will compare a standard anti-rejection therapy to an experimental anti-rejection therapy. The study will look carefully at how well the experimental anti-rejection therapy works and how it may be potentially less harmful to the transplanted kidney. Participants will be randomly assigned to receive either the standard therapy (CellCept & standard dose tacrolimus) or the experimental therapy combination(Zortress (everolimus) plus lower dose tacrolimus).
 
 

Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Imunosuppression Trial (BENEFIT)

This study is designed for adults who receive a kidney transplant. It is designed to compare standard anti-rejection medicine to an experimental anti-rejection medicine, Belatacept. It will look carefully at how well the anti-rejection medicine works and if it may be potentially less harmful to the transplanted kidney. Participants will be randomly assigned to receive standard medicine (cyclosporine) or the experimental medicine (Belatacept).

 
 

A transplant is the replacement of a patient's diseased organ(s) with a normal organ(s) from someone called a donor. The donor's organ(s) is completely removed and quickly transported to the patient, who may be located across the country. Organs are cooled and kept in a special solution while being taken to the patient.

After a transplant, patients must take several medications. The most important are those to keep the body from rejecting the transplant. These medications, which must be taken for life, can cause significant side effects, including hypertension, fluid retention, tremors, excessive hair growth, and possible kidney damage. To combat these problems, additional drugs are often prescribed.

Research in the field of transplantations involves studies on the techniques used for transplantation and of the medications used to treat transplant patients.